NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients whose first treatment stopped working
Disease control OngoingThis study tests whether adding the experimental drug AK112 to standard chemotherapy can help people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer with an EGFR mutation) whose cancer has worsened after initial targeted therapy. About 420 pa…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lung cancer patients who stop responding to targeted drugs
Disease control OngoingThis phase 3 trial tests whether adding the experimental drug AK112 (ivonescimab) to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) whose cancer has worsened after targeted therapy. About 322 participants will re…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. Abo…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC